FINNENCE ▪ THE WIRE FILE
THE WIRE · № 75602
News■ Unclear/unknown
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
FDA Phase 2 clearance for a Chinese CAR-T is a pipeline milestone but the company is not in the slug list.
Early-stage China biotech milestone, no listed ticker
CATALYST TO WATCH
Phase 2 enrollment and interim data
MAIN RISK
Clinical failure in brain metastases
FULL DISPATCH
BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDChina
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares China
IT'S BACK. THAT'S BIG. The All-Electric smart #2 Makes Its World Premiere at the Paris Motor Show2026-10-12 10:54 UTC
IT'S BACK. THAT'S BIG. The All-Electric smart #2 Makes Its World Premiere at the Paris Motor Show2026-10-12 10:54 UTC
→CORRELATIONshares China
Global diesel shortage: why Gulf refined fuel exports lag crude oil shipments2026-10-12 11:00 UTC
Global diesel shortage: why Gulf refined fuel exports lag crude oil shipments2026-10-12 11:00 UTC
→CORRELATIONshares China
The EU-China trade and investment understanding: a welcome buying of time2026-10-12 11:06 UTC
The EU-China trade and investment understanding: a welcome buying of time2026-10-12 11:06 UTC
→CORRELATIONshares Healthcare
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer2026-10-12 11:00 UTC
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer2026-10-12 11:00 UTC
→CORRELATIONshares Healthcare
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
→CORRELATIONshares Healthcare
Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting2026-10-12 11:30 UTC
Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting2026-10-12 11:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.